Diamyd Medical to present this week at LSX World Congress and at Swiss-Nordic Bio 2020
Final results from the DIAGNODE-1 trial and additional insights into the comprehensive analysis of previous clinical trials will be presented by CEO Ulf Hannelius at LSX World Congress in London on 4-5 February and by founder and Board Director Anders Essen-Möller at Swiss-Nordic BIO 2020 in Zürich on 6 February.Diamyd Medical announced topline results from DIAGNODE-1 in December 2019, showing a positive disease progression at 30 months from baseline and that an additional booster-injection given to three patients prolonged the preservation of endogenous insulin production by an additional